Cargando…

The Role of Genetic Polymorphisms in High-Dose Methotrexate Toxicity and Response in Hematological Malignancies: A Systematic Review and Meta-Analysis

Objective: High-dose methotrexate (HDMTX) is a mainstay therapeutic agent for the treatment of diverse hematological malignancies, and it plays a significant role in interindividual variability regarding the pharmacokinetics and toxicity. The genetic association of HDMTX has been widely investigated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Zaiwei, Hu, Yang, Liu, Shuang, Jiang, Dan, Yi, Zhanmiao, Benjamin, Mason M., Zhao, Rongsheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570281/ https://www.ncbi.nlm.nih.gov/pubmed/34744734 http://dx.doi.org/10.3389/fphar.2021.757464

Ejemplares similares

Toward Therapeutic Drug Monitoring of Lenalidomide in Hematological Malignancy? Results of an Observational Study of the Exposure-Safety Relationship
por: Song, Zaiwei, et al.
Publicado: (2022)

Association between high-dose methotrexate-induced toxicity and polymorphisms within methotrexate pathway genes in acute lymphoblastic leukemia
por: Xu, Meng, et al.
Publicado: (2022)

Evaluation, Identification, and Management of Acute Methotrexate Toxicity in High-dose Methotrexate Administration in Hematologic Malignancies
por: Feinsilber, Doron, et al.
Publicado: (2018)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

Effect of Polymorphisms of ABCB1 and MTHFR on Methotrexate-Related Toxicities in Adults With Hematological Malignancies
por: Han, Jian, et al.
Publicado: (2021)

Knowledge, Attitudes and Practice of Healthcare Providers, Healthcare Regulatory Practitioners and Patients Toward Biosimilars in China: Insights From a Nationwide Survey
por: Hu, Yang, et al.
Publicado: (2022)

Intracranial Hemorrhage Following Oral Low-Dose Methotrexate After Multiple Toxicities Caused by High-Dose Methotrexate in Childhood Acute Lymphoblastic Leukemia
por: Xin, Ning, et al.
Publicado: (2019)

A Risk Scoring Model for High-Dose Methotrexate-Induced Liver Injury in Children With Acute Lymphoblastic Leukemia Based on Gene Polymorphism Study
por: He, Xia, et al.
Publicado: (2021)

Preventing and Managing Toxicities of High-Dose Methotrexate
por: Howard, Scott C., et al.
Publicado: (2016)

Impact of microRNA polymorphisms on high-dose methotrexate-related hematological toxicities in pediatric acute lymphoblastic leukemia
por: Zhan, Min, et al.
Publicado: (2023)

Ancestry and TPMT-VNTR Polymorphism: Relationship with Hematological Toxicity in Uruguayan Patients with Acute Lymphoblastic Leukemia
por: Burgueño-Rodríguez, Gabriela, et al.
Publicado: (2020)

Genetic Polymorphisms of TYMS, MTHFR, ATIC, MTR, and MTRR Are Related to the Outcome of Methotrexate Therapy for Rheumatoid Arthritis in a Chinese Population
por: Lv, Shuang, et al.
Publicado: (2018)

PROTACs: Walking through hematological malignancies
por: Bou Malhab, Lara J., et al.
Publicado: (2023)

Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia
por: Liu, Shu-Guang, et al.
Publicado: (2017)

Genetic determinants for methotrexate response in juvenile idiopathic arthritis
por: Pastore, Serena, et al.
Publicado: (2015)

Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma
por: Park, Jeong A, et al.
Publicado: (2016)

More severe toxicity of genetic polymorphisms on MTHFR activity in osteosarcoma patients treated with high-dose methotrexate
por: Xie, Lu, et al.
Publicado: (2017)

Predicted Vancomycin Dosage Requirement in Patients With Hematological Malignancies and Dosage Dynamic Adjustment
por: Song, Xiangqing, et al.
Publicado: (2022)

Application of cell-derived exosomes in the hematological malignancies therapy
por: Ghaffari, Kazem, et al.
Publicado: (2023)

Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia
por: Gervasini, Guillermo, et al.
Publicado: (2012)

The influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in children with non-Hodgkin malignant lymphoma
por: Erculj, Nina, et al.
Publicado: (2014)

Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A Systematic Review and Meta-Analysis of Clinical Trials
por: Li, Qingfang, et al.
Publicado: (2019)

High-Dose Methotrexate-Induced Idiopathic Intracranial Hypertension in Infant Acute Lymphoblastic Leukemia
por: Zhang, Yazhi, et al.
Publicado: (2020)

Population Pharmacokinetics of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia
por: Gao, Xuan, et al.
Publicado: (2021)

Protective Effects of Magnesium Glycyrrhizinate on Methotrexate-Induced Hepatotoxicity and Intestinal Toxicity May Be by Reducing COX-2
por: Cao, Yuzhu, et al.
Publicado: (2019)

Relationship Between the Free and Total Methotrexate Plasma Concentration in Children and Application to Predict the Toxicity of HD-MTX
por: Dong, Wei-Chong, et al.
Publicado: (2021)

Effects of genetic polymorphisms on methotrexate levels and toxicity in Chinese patients with acute lymphoblastic leukemia
por: Hao, Qishan, et al.
Publicado: (2022)

CYP2J2(∗)7 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose Intensity in Ethiopian Breast Cancer Patients
por: Ahmed, Jemal Hussien, et al.
Publicado: (2019)

Effectiveness and Safety of Iguratimod Monotherapy or Combined With Methotrexate in Treating Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
por: Ouyang, Dan, et al.
Publicado: (2022)

Toward therapeutic drug monitoring of citalopram in depression? Insights from a systematic review
por: Xu, Na, et al.
Publicado: (2023)

Population Pharmacokinetics of Brentuximab Vedotin in Adult and Pediatric Patients With Relapsed/Refractory Hematologic Malignancies: Model‐Informed Hypothesis Generation for Pediatric Dosing Regimens
por: Suri, Ajit, et al.
Publicado: (2020)

Low-Dose Methotrexate Toxicity Presenting as Pancytopenia
por: Dhillon, Gundip S, et al.
Publicado: (2022)

Association Study Among Candidate Genetic Polymorphisms and Chemotherapy-Related Severe Toxicity in Testicular Cancer Patients
por: Lavanderos, María A., et al.
Publicado: (2019)

Assessment and Comparison of the Efficacy of Methotrexate, Prednisolone, Adalimumab, and Tocilizumab on Multipotency of Mesenchymal Stem Cells
por: Liu, Shuang, et al.
Publicado: (2020)

Histone Deacetylase 6 as a Therapeutic Target in B cell-associated Hematological Malignancies
por: Yang, Jia, et al.
Publicado: (2020)

Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study
por: Li, Na, et al.
Publicado: (2023)

Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study
por: Goswami, Pushpendra, et al.
Publicado: (2020)

Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO
por: Goswami, Pushpendra, et al.
Publicado: (2020)

Meta-Analysis of ABCG2 and ABCB1 Polymorphisms With Sunitinib-Induced Toxicity and Efficacy in Renal Cell Carcinoma
por: Sun, Fengjun, et al.
Publicado: (2021)

Osteonecrosis of the jaw induced by immune checkpoint inhibitors: an urgent need for attention
por: Li, Xinya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h6vbo80i6co2ocqll2bu963pda